On Friday, Moderna Inc. (MRNA) revealed its fourth-quarter financial results, which despite surpassing revenue expectations, showcased a deeper-than-anticipated lossSuch figures signify the company’s ongoing struggles as it trims costs amidst plummeting demand for its COVID-19 vaccine, a flagship product that once propelled its growth.

This latest financial snapshot reflects another quarter of growing pains for the biotech firm, now eager to re-establish its footing in the market while simultaneously courting new product streamsThe fallout from the pandemic has left a trail of rapid transformations—once booming, Moderna's revenues have sharply declined as the frenzy surrounding COVID-19 vaccinations has subsided.

Following the announcement, Moderna's stock took a hit during pre-market trading, dipping over 4%, showcasing investor anxieties regarding the financial forecast and overall health of the company.

The report indicates that Moderna faced a staggering net loss of $1.12 billion in the fourth quarter, translating to a loss of $2.91 per share, marking the fifth consecutive quarter of losses for the firmIn contrast, the same period last year had seen a net profit of $217 million, equating to earnings of 55 cents per share, while market analysts had projected a smaller loss of $2.68 per share.

In breaking down the losses, it was noted that the quarter's financial struggles included approximately $238 million attributed to non-cash expenses related to the termination of a contract manufacturing agreement, a decision which has raised eyebrows among stakeholders.

Jamey Mock, Moderna's Chief Financial Officer, noted in a subsequent interview that one of the significant takeaways for 2024 is the company’s ability to cut costs by 27% compared to 2023. There are ambitious plans for further reductions, with expectations to slice off an additional $1 billion in expenses by the end of 2025.

The company reaffirmed its revenue forecast for 2025, projecting product sales to range between $1.5 billion and $2.5 billion, with the bulk expected to materialize in the latter half of the year

Advertisements

Historically, demand for respiratory products surges in the fall and winter months, leading to a conservative estimate of a mere $200 million in sales in the first half of the year.

In January, Moderna significantly slashed its 2025 sales forecast by approximately $1 billion, a move that shocked the market and triggered a steep fall in its stock price, reflecting the volatility surrounding its revenue projectionsThe stock has declined over 20% thus far this year, which is a telling indicator of diminishing confidence among investors.

This downward adjustment was triggered by heightened competition in the COVID-19 vaccine market, a decline in vaccination rates, and uncertainties surrounding production timelines stemming from agreements with a limited number of countriesFurthermore, there was ambiguity concerning the recommendations for a respiratory syncytial virus (RSV) vaccine booster from the Centers for Disease Control and Prevention (CDC).

Mock warned, “Should all these potential headwinds materialize, it would push our performance toward the lower end of our expected range.” He emphasized Moderna’s determination to “navigate” these challenges moving forward.

In terms of sales performance, Moderna reported fourth-quarter revenues of $966 million—less than half of the $2.8 billion recorded the previous yearHowever, this figure surpassed market expectations of $942.8 million, signaling a modest beat in this turbulent environment.

The bulk of the company's revenue continues to come from its COVID-19 vaccine, which recorded sales of $923 million—a 66% decline year-over-year, falling short of analysts' estimates of $909 millionBreaking it down, domestic sales accounted for $244 million while international sales reached $679 million.

Moderna attributed the sales drop to the previous year’s earlier-than-expected launch of its latest COVID-19 vaccine version, which effectively pulled revenue from the fourth quarter into the third

Advertisements

They also indicated that the U.SFood and Drug Administration (FDA) approved the new vaccine three weeks earlier than in 2023, allowing Moderna to better meet demand ahead of the fourth quarter.

As for international sales, they have also dipped due to a gradual wind-down of pre-purchase agreements with certain countriesThis indicates a strategic pivot as Moderna reassesses its global market approach.

The fourth-quarter revenue also includes $15 million from sales of its RSV vaccine within the U.S., which exceeded analysts' expectations of $13 millionThe vaccine, approved in May of the previous year, was rolled out to older adults in the fall and winter months, marking a critical expansion for Moderna as it continues to diversify beyond its COVID-19 offerings.

Currently, Moderna’s RSV vaccine holds approval in various regions, including the U.S., the European Union, Canada, Norway, Iceland, and Qatar for individuals aged 60 and above—further extending its reach in critical demographic segments.

The company appears fixated on enhancing its product lineup through its mRNA platform, the technology powering both the COVID-19 and RSV vaccinesModerna is ambitiously targeting the approval of 10 new products over the next three years, a significant expansion of its product portfolio.

In the fourth quarter alone, Moderna submitted requests for regulatory approval for three new mRNA productsThis includes a “next-generation” COVID-19 vaccine, a combined vaccine targeting both COVID-19 and influenza, as well as an RSV vaccine aimed at high-risk adults aged 18 to 59. Mock indicated that the FDA is expected to make a determination regarding the next-generation COVID-19 vaccine by May, with potential expansion of RSV vaccine approval in June.

Moreover, Moderna is developing a standalone influenza vaccine, a personalized cancer vaccine in collaboration with Merck (MRK), as well as vaccines targeting latent viruses

Advertisements

Advertisements

Advertisements